STOCK TITAN
  1. Home
  2. Sec-filings
  3. BNTX
  4. [Form 3/A] BioNTech SE Amended Initial Statement of Beneficial Ownership

BioNTech (BNTX) CEO discloses 39.2M indirect ordinary shares

Filing Impact
(Neutral)
Filing Sentiment
(Neutral)
Form Type
3/A

Rhea-AI Filing Summary

BioNTech SE Chief Executive Officer Ugur Sahin filed an amended insider ownership report that updates his indirect holdings in the company. The filing shows 39,218,111 ordinary shares are held by Medine GmbH, an entity of which he is the sole shareholder.

Within this amount, 106,721 ordinary shares are held for the benefit of an individual under a trust arrangement. Medine GmbH has voting power, but not dispositive power, over those trust shares. Sahin may be deemed to beneficially own the ordinary shares held by Medine GmbH, and the amendment does not report any new purchases or sales.

Positive

  • None.

Negative

  • None.
Insider Sahin Ugur
Role Chief Executive Officer
Type Security Shares Price Value
holding Ordinary Shares -- -- --
Holdings After Transaction: Ordinary Shares — 39,218,111 shares (Indirect, See Footnote)
Footnotes (1)
  1. [object Object]
Indirectly held ordinary shares 39,218,111 shares Indirect holdings via Medine GmbH reported in Form 3/A
Trust-held ordinary shares 106,721 shares Shares held for an individual under a trust arrangement
Insider holding entries 1 entry Single indirect ownership line item in transaction summary
Net buy/sell shares in filing 0 shares Transaction summary shows neutral net buy/sell direction
beneficially own financial
"The Reporting Person may be deemed to beneficially own the ordinary shares"
Beneficially own means having the economic rights and risks of a security—such as the right to receive dividends, sell the shares, or profit from price changes—whether or not your name appears on the official share register. Think of it like renting a car: you use it and reap the benefits even if the title lists someone else. Investors care because beneficial ownership determines who truly controls value, must be disclosed under securities rules, and can signal potential influence or trading activity that affects a stock’s price.
dispositive power financial
"Medine GmbH exercises voting power, but not dispositive power, over such ordinary shares"
Dispositive power is the authority to decide the final outcome of an asset, legal claim, contract, or corporate action — in effect the power to dispose of or resolve something. For investors it matters because whoever holds that authority can determine who gets paid, who controls an asset or vote, and how risks and returns are allocated; think of it like holding the key that lets you lock in the winner or loser in a deal.
voting power financial
"Medine GmbH exercises voting power, but not dispositive power, over such ordinary shares"
Voting power is the ability shareholders have to influence a company's major decisions—like electing the board, approving mergers, or changing corporate rules—based on the voting rights attached to the shares they hold. For investors it matters because greater voting power is like holding more keys to a building: it gives you a stronger say over management choices and the company’s strategy, which can affect future value and risk.
trust arrangement financial
"ordinary shares noted herein are held for the benefit of an individual under a trust arrangement"
indirect financial
"total_shares_following_transaction ... ownership_type: indirect"
Understanding Insider Trading Forms →
SEC Form 3
FORM 3UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number:3235-0104
Estimated average burden
hours per response:0.5
1. Name and Address of Reporting Person*
Sahin Ugur
(Last)(First)(Middle)
C/O BIONTECH SE
AN DER GOLDGRUBE 12
(Street)
MAINZD-55131
(City)(State)(Zip)
GERMANY
(Country)		2. Date of Event Requiring Statement (Month/Day/Year)
03/18/2026		3. Issuer Name and Ticker or Trading Symbol
BioNTech SE [ BNTX ]
3a. Foreign Trading Symbol
5. If Amendment, Date of Original Filed (Month/Day/Year)
03/25/2026
4. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
DirectorX10% Owner
XOfficer (give title below)Other (specify below)
Chief Executive Officer
6. Individual or Joint/Group Filing (Check Applicable Line)
XForm filed by One Reporting Person
Form filed by More than One Reporting Person
Table I - Non-Derivative Securities Beneficially Owned
1. Title of Security (Instr. 4) 2. Amount of Securities Beneficially Owned (Instr. 4) 3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5) 4. Nature of Indirect Beneficial Ownership (Instr. 5)
Ordinary Shares39,218,111ISee Footnote(1)
Table II - Derivative Securities Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 4) 2. Date Exercisable and Expiration Date (Month/Day/Year)3. Title and Amount of Securities Underlying Derivative Security (Instr. 4) 4. Conversion or Exercise Price of Derivative Security 5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5) 6. Nature of Indirect Beneficial Ownership (Instr. 5)
Date ExercisableExpiration DateTitleAmount or Number of Shares
Explanation of Responses:
1. The ordinary shares are held by Medine GmbH. The Reporting Person is the sole shareholder of Medine GmbH. 106,721 of the ordinary shares noted herein are held for the benefit of an individual under a trust arrangement, pursuant to which Medine GmbH exercises voting power, but not dispositive power, over such ordinary shares for so long as such ordinary shares are held in trust. The Reporting Person may be deemed to beneficially own the ordinary shares held by Medine GmbH.
Remarks:
This Form 3 is being filed to correct the number of shares beneficially owned by the Reporting Person through Medine GmbH, which was inadvertently misreported on the Reporting Person's Form 3 filed on March 25, 2026.
/s/ Humza Bokhari, Attorney-in-Fact04/13/2026
** Signature of Reporting PersonDate
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 5 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 3: SEC 1473 (03-26)

Source: View Original Filing on SEC EDGAR

FAQ

What does Ugur Sahin’s Form 3/A filing show for BioNTech (BNTX)?

The Form 3/A shows Ugur Sahin indirectly holds 39,218,111 BioNTech ordinary shares through Medine GmbH. This amended filing updates his beneficial ownership disclosure without reporting any new share purchases or sales.

How many BioNTech (BNTX) shares are held through Medine GmbH?

Medine GmbH holds 39,218,111 BioNTech ordinary shares for the benefit of Ugur Sahin. As sole shareholder of Medine GmbH, Sahin may be deemed to beneficially own these indirectly held shares under securities disclosure rules.

What is the trust arrangement mentioned in the BioNTech (BNTX) Form 3/A?

The filing states 106,721 ordinary shares are held for an individual under a trust. Medine GmbH exercises voting power, but not dispositive power, over these trust shares as long as they remain in the trust structure.

Does the BioNTech (BNTX) Form 3/A report insider buying or selling by Ugur Sahin?

No, this Form 3/A does not report any share purchases or sales. It functions as an amended ownership statement, clarifying how many BioNTech ordinary shares are indirectly held and how some of them are structured through a trust.

How is beneficial ownership described for Ugur Sahin in the BioNTech (BNTX) filing?

The filing explains that Ugur Sahin may be deemed to beneficially own the BioNTech ordinary shares held by Medine GmbH. This reflects his status as sole shareholder of Medine GmbH, which directly holds the disclosed share position.